{
    "clinical_study": {
        "@rank": "160025", 
        "arm_group": {
            "arm_group_label": "bismuth Bi 213 monoclonal antibody M195 & cytarabine", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive cytarabine IV continuously on days 1-5. Beginning between days 7 and 14, patients receive Bi213 MOAB M195 IV over 5 minutes up to 4 times daily over 1-4 days. Patient also receive filgrastim (G-CSF) subcutaneously daily beginning 24 hours after the final Bi213 MOAB M195 infusion and continuing until blood counts recover. Treatment continues in the absence of disease progression or unacceptable toxicity.\nCohorts of 3 to 6 patients receive escalating doses of Bi213 MOAB M195 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, subsequent patients are treated at the MTD.\nPatients are followed twice weekly for 4 weeks and then monthly for 3 months"
        }, 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing\n      so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy may\n      kill more cancer cells.\n\n      PURPOSE: Phase I/II trial to study the effectiveness of combining chemotherapy and\n      monoclonal antibody therapy in treating patients who have advanced myeloid cancer."
        }, 
        "brief_title": "Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer", 
        "completion_date": {
            "#text": "December 2009", 
            "@type": "Actual"
        }, 
        "condition": [
            "Leukemia", 
            "Myelodysplastic Syndromes", 
            "Myelodysplastic/Myeloproliferative Neoplasms"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Leukemia", 
                "Myelodysplastic Syndromes", 
                "Preleukemia", 
                "Myeloproliferative Disorders", 
                "Myelodysplastic-Myeloproliferative Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the maximum tolerated dose of bismuth Bi 213 monoclonal antibody M195\n           following cytarabine in patients with advanced myeloid malignancies.\n\n        -  Determine the antileukemic effects of this treatment in this patient population.\n\n        -  Determine the toxicity of this treatment in this patient population.\n\n        -  Determine the complete remission rate of patients treated with this treatment regimen.\n\n      OUTLINE: This is a dose escalation study of bismuth Bi 213 monoclonal antibody M195 (Bi213\n      MOAB M195).\n\n      Patients receive cytarabine IV continuously on days 1-5. Beginning between days 7 and 14,\n      patients receive Bi213 MOAB M195 IV over 5 minutes up to 4 times daily over 1-4 days.\n      Patient also receive filgrastim (G-CSF) subcutaneously daily beginning 24 hours after the\n      final Bi213 MOAB M195 infusion and continuing until blood counts recover. Treatment\n      continues in the absence of disease progression or unacceptable toxicity.\n\n      Cohorts of 3 to 6 patients receive escalating doses of Bi213 MOAB M195 until the maximum\n      tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients\n      experience dose-limiting toxicity. Once the MTD is determined, subsequent patients are\n      treated at the MTD.\n\n      Patients are followed twice weekly for 4 weeks and then monthly for 3 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  One of the following diagnoses:\n\n               -  Pathologically confirmed acute myeloid leukemia (AML) meeting one of the\n                  following criteria:\n\n                    -  Newly diagnosed AML, over age 60, and not eligible for higher priority\n                       protocols\n\n                    -  Newly diagnosed AML and unable to receive anthracycline-containing or\n                       high-dose cytarabine-containing regimens\n\n                    -  AML in relapse\n\n                    -  AML refractory to two courses of standard induction chemotherapy or one\n                       course of high-dose cytarabine-containing induction chemotherapy\n\n               -  Chronic myelogenous leukemia in accelerated phase or myeloid blast crisis\n\n               -  Refractory anemia with excess blasts (RAEB), RAEB in transformation, or chronic\n                  myelomonocytic leukemia\n\n          -  More than 25% of bone marrow blasts must be CD33 positive\n\n          -  Not a candidate for immediate bone marrow transplantation with a HLA-compatible donor\n\n          -  No active CNS leukemia\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  Not specified\n\n        Performance status:\n\n          -  Karnofsky 60-100%\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Not specified\n\n        Hepatic:\n\n          -  Bilirubin no greater than 2 mg/dL (unless due to leukemia or Gilbert's disease)\n\n          -  Alkaline phosphatase no greater than 2.5 times upper limit of normal (ULN)\n\n          -  AST no greater than 2.5 times ULN\n\n        Renal:\n\n          -  Creatinine less than 2 mg/dL OR\n\n          -  Creatinine clearance greater than 60 mL/min\n\n        Cardiovascular:\n\n          -  No New York Heart Association class III or IV cardiac disease\n\n        Pulmonary:\n\n          -  No pulmonary disease\n\n        Other:\n\n          -  No detectable antibodies to monoclonal antibody M195\n\n          -  No serious active uncontrolled infection\n\n          -  No other concurrent active malignancy requiring therapy\n\n          -  No other serious or life-threatening conditions that would preclude study\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  At least 3 weeks since prior biologic therapy and recovered\n\n        Chemotherapy:\n\n          -  See Disease Characteristics\n\n          -  Prior hydroxyurea allowed if discontinued before study treatment\n\n          -  At least 3 weeks since other prior chemotherapy and recovered\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  At least 3 weeks since prior radiotherapy and recovered\n\n        Surgery:\n\n          -  Not specified"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 10, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00014495", 
            "org_study_id": "00-117", 
            "secondary_id": [
                "MSKCC-00117", 
                "NCI-H01-0071"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "bismuth Bi 213 monoclonal antibody M195 & cytarabine", 
                "intervention_name": "filgrastim", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "bismuth Bi 213 monoclonal antibody M195 & cytarabine", 
                "intervention_name": "cytarabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "bismuth Bi 213 monoclonal antibody M195 & cytarabine", 
                "intervention_name": "bismuth Bi213 monoclonal antibody M195", 
                "intervention_type": "Radiation"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Immunoglobulins", 
                "Antibodies, Monoclonal", 
                "Cytarabine", 
                "Lenograstim", 
                "Bismuth"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "recurrent childhood acute myeloid leukemia", 
            "recurrent adult acute myeloid leukemia", 
            "accelerated phase chronic myelogenous leukemia", 
            "blastic phase chronic myelogenous leukemia", 
            "untreated adult acute myeloid leukemia", 
            "untreated childhood acute myeloid leukemia and other myeloid malignancies", 
            "refractory anemia with excess blasts", 
            "refractory anemia with excess blasts in transformation", 
            "chronic myelomonocytic leukemia", 
            "previously treated myelodysplastic syndromes", 
            "secondary myelodysplastic syndromes", 
            "childhood chronic myelogenous leukemia", 
            "atypical chronic myeloid leukemia, BCR-ABL1 negative", 
            "myelodysplastic/myeloproliferative neoplasm, unclassifiable", 
            "adult acute myeloid leukemia with t(8;21)(q22;q22)", 
            "adult acute myeloid leukemia with t(16;16)(p13;q22)", 
            "adult acute myeloid leukemia with inv(16)(p13;q22)", 
            "adult acute myeloid leukemia with 11q23 (MLL) abnormalities", 
            "adult acute myeloid leukemia with t(15;17)(q22;q12)", 
            "childhood myelodysplastic syndromes"
        ], 
        "lastchanged_date": "April 16, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/MSKCC-00117"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10021"
                }, 
                "name": "Memorial Sloan - Kettering Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I/II Trial Of Sequential Therapy With Cytarabine And Bismuth-213-Labeled HuM195 (Humanized Anti-CD33) In Patients With Advanced Myeloid Malignancies", 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Joseph G. Jurcic, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum tolerated dose", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Antileukemic effects", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Pharmacology, biodistribution, and dosimetry", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00014495"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": [
            {
                "PMID": "20858843", 
                "citation": "Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS, Heaney ML, Chanel S, Morgenstern A, Sgouros G, Larson SM, Scheinberg DA, Jurcic JG. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res. 2010 Nov 1;16(21):5303-11. Epub 2010 Sep 21."
            }, 
            {
                "citation": "Mulford DA, Pandit-Taskar N, McDevitt MR, et al.: Sequential therapy with cytarabine and bismuth-213 (213Bi)-labeled-HuM195 (Anti-CD33) for acute myeloid leukemia (AML). [Abstract] Blood 104 (11): A-1790, 2004."
            }
        ], 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2000", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }, 
    "geocoordinates": {
        "Memorial Sloan - Kettering Cancer Center": "40.714 -74.006"
    }
}